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ABSTRACT The resistance rates of intestinal Escherichia
coli populations from poultry were determined during
treatment and withdrawal period with 3 antimicrobial
agents commonly used as therapeutics in poultry medi-
cine. A total of 108 chickens were considered: 18 were
treated orally with enrofloxacin, 18 with doxycycline, and
18 with sulfonamides, whereas another 18 chickens were
maintained as controls for each antimicrobial group. Fecal
samples were taken during the treatment and after the
withdrawal period, and E. coli were isolated through Flu-
orocult media plating. A total of 648 E. coli strains (216 per
antimicrobial tested) were isolated and identified though
biochemical methods. Minimal inhibitory concentrations
to the antimicrobials used were also determined using a
broth microdilution method. The resistance rates of intes-
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INTRODUCTION
The risks associated with the use of antimicrobial
agents for the therapeutic treatment of sick animals have
been the subject of debate in recent years. Some scientists
are very concerned about the potential consequences,
such as the development and spread of bacterial resis-
tance, whereas other researchers state that there is not
enough evidence that might point toward such potential
risk or even consider potential human health benefits
derived from antibiotic use in food animals (Witte, 1998;
Doyle, 2006).
In poultry farming, as well as with other intensively
reared animals, antibiotics may be administered though
feed or drinking water to whole flocks rather than to
individual animals. In the European community (EC), the
water- or feed-based administration of antimicrobials to
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tinal E. coli to all of the antimicrobials tested significantly
increased during the course of the therapeutic treatment.
In addition, significant differences (P = 0.0136) in resis-
tance rates persisted between the intestinal E. coli of the
enrofloxacin-treated and control batches until the end
of the withdrawal period, but this difference was not
observed for the cases of doxycycline or sulfonamides
treatments. Antimicrobial use in poultry medicine seems
to select for antimicrobial-resistant strains of pathogenic
bacterial species such as E. coli. In some cases, the higher
frequencies of resistant strains may persist in the avian
intestinal tract until the end of the withdrawal period,
when it is legal to use these animals for human con-
sumption.
animals (at lower doses than those employed for thera-
peutic purposes) to enhance animal growth has been com-
pletely banned since January 2006. After the ban of the
use of avoparcin, bacitracin, tylosin, espiramicin, and vir-
giniamicin as growth promoters in the 1990s, the level
of bacterial resistance to such antimicrobials decreased
considerably. Nevertheless, increasing amounts of anti-
microbial agents have been used with therapeutic pur-
poses in veterinary medicine since this ban (Monnet, 2000;
Phillips et al., 2003). From among these agents, together
with tetraciclines, quinolones, and sulfonamides, form
some of the most widely used antimicrobial families in
poultry therapy (Avrain et al., 2003; Phillips et al., 2003;
Patel et al., 2004; Posyniak et al., 2005).
Escherichia coli is commonly found in the intestinal tract
of humans and animals. Its use as an indicator bacterium
is useful because this microorganism acquires antimicro-
bial resistance faster than other conventional bacteria.
Thus, changes in the resistance of this species may serve
as a good indicator of resistance in potentially pathogenic
bacteria (Kijima-Tanaka et al., 2003; Von Baum and
Marre, 2005).
MIRANDA ET AL.1644
Poultry food products are an important source of E.
coli because, at the time of slaughter, fecal contamination
from the gut readily contaminates poultry carcasses. As
a result, poultry meat may be contaminated with fecal
material or ingesta and with bacteria associated with
these contaminants (Sáenz et al., 2001; Van den Bogaard
et al., 2001; Smith et al., 2007). Other authors have re-
ported that vegetables may also be contaminated from
animals via sewage and manure, which may act as a
source of contamination by resistant bacteria (Phillips et
al., 2003). These resistant bacteria may colonize the human
intestinal tract and may also be involved in the transfer-
ence of resistance genes to human endogenous microflora
(Van den Bogaard et al., 2001). Hence, resistant E. coli
from poultry selected during veterinary antimicrobial
treatments can infect humans directly and via food.
The aims of the present work were to determine the
degree of antimicrobial resistance of E. coli during the
most commonly used antimicrobial treatments and after
their withdrawal period. The withdrawal period is de-
termined as a function of the persistence of antimicrobial
residues in animal tissues. Thus, it is of crucial interest
to investigate the resistance rates of the bacterial popula-
tions present in the animals’ intestines because this may
provide valuable information for establishing the safety




A total of 108 healthy male “label” chickens aged 4 to
6 wk obtained from the same commercial hatchery were
used. The chickens were fed with the same antimicrobial-
free feed before starting antimicrobial treatment. These
chickens were split into 3 groups of 36 animals per group.
In each of these 3 groups, 18 broilers were treated with
a therapeutic antimicrobial dosage and another 18 were
maintained as controls. None of the chickens had direct
physical contact with any of the other chickens during
the assays because they were housed in individual cages
in the animal facility. Contamination between the treated
and untreated batches was prevented by housing them
in different rooms. The poultry were fed twice daily with
antibimicrobial-free commercial poultry feed and had
free access to the medicated water, in the case of the
treated poultry, or to antimicrobial-free water, in the case
of the control batches. Determination of water intake was
performed at 12-h intervals.
All parts of this study were carried out according to
EC council directives concerning the laws, regulations,
and administrative provisions of the member states re-
garding the protection of animals used for experimental
and other scientific purposes.
Enrofloxacin Treatment
Eighteen chickens were weighed and treated with a
therapeutic dose of enrofloxacin in water (0.05 g/L) of
Colmyc-E (S.P. Veterinaria, Tarragona, Spain), and an-
other 18 were weighed and kept untreated as controls.
The treatment was administered over 5 d, keeping a pe-
riod of 12 d as the withdrawal time, in accordance with
the instructions of the manufacturer. Each group of chick-
ens was sampled immediately before starting treatment
(d 0), on the first day of treatment (d 1), in the middle of
treatment (d 3), on the last day of treatment (d 5), in the
middle of the withdrawal period (d 11), and after the
withdrawal time had ended (d 17).
Doxycycline Treatment
Eighteen chickens were weighed and treated with a
therapeutic dose of doxycycline in water (1 g/L) of Doxi-
dol (Fatro Uriach Veterinaria, Barcelona, Spain), and an-
other 18 were weighed and kept as controls. The treat-
ment was administered over 5 d, keeping a period of 7
d as the withdrawal time, in accordance with the manu-
facturer’s instructions. Each group of chickens was sam-
pled immediately before starting treatment (d 0), on the
first day of treatment (d 1), in the middle of treatment (d
3), on the last day of treatment (d 5), in the middle of the
withdrawal period (d 8), and after the withdrawal time
had ended (d 12).
Sulfonamides Treatment
Eighteen chickens were weighed and treated with a
therapeutic dose of a sulfonamides mixture (1.33 g of
Sulfaquinoxaline + 1.66 g of Sulfamethazine + 1.66 g of
Sulfameracine + 3.33 g of Sulfisoxazole/100 mL) in water
(15 mL/L) from Cunisan Aviar (Arimany, Barcelona,
Spain), and another 18 were weighed and kept as controls.
The treatment was administered over 4 d, followed by 2
d of repose and another 3 d of treatment, in accordance
with the instructions on the package insert. After treat-
ment, a withdrawal period of 15 d was kept. Each group
of chickens was sampled immediately before starting
treatment (d 0), on the first day on treatment (d 1), on
the fourth day of treatment (d 4), on the last day of treat-
ment (d 9), in the middle of the withdrawal period (d
16), and after the withdrawal time had ended (d 24).
For the 3 antimicrobials tested, fecal samples were
taken by swabbing the cloacae of each chicken with sterile
swabs to obtain a minimum of 0.5 g of fecal matter, which
was placed aseptically in a sterile tube. These samples
were taken to the laboratory in an ice chest in less than
half an hour for immediate processing.
Isolation and Identification of E. coli
The fecal samples of 3 animals belonging to the same
group were placed together in a sterile masticator bag
with an appropriate volume (1/9, wt/vol) of sterile buf-
fered peptone water (Merck, Darmstadt, Germany) and
subsequently homogenized with a masticator (Aes, Com-
bourg, France) for 2 m. After homogenization, samples
were tested for isolation and identification of E. coli. One
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Table 1. Minimum inhibitory concentration (MIC) for 50% (MIC50) and 90% (MIC90), MIC ranges and resistance
rates for Escherichia coli strains obtained from treated and control chickens during and after enrofloxacin applica-
tion in the drinking water1
Sampling day
Item 0 1 3 5 11 17
Treated chickens
n strains 18 18 18 18 18 18
MIC50 0.5 4 4 8 4 4
MIC90 8 16 16 8 8 16
Range <0.125 to 8 <0.125 to 16 <0.125 to 16 <0.125 to 8 0.5 to 32 <0.125 to 8
n resistant (%) 6 (33.3) 13 (72.2) 15 (83.3) 16 (88.9) 16 (88.9) 16 (88.9)
Control chickens
n strains 18 18 18 18 18 18
MIC50 <0.125 <0.125 <0.125 <0.125 <0.125 <0.125
MIC90 8 8 8 8 4 4
Range <0.125 to 8 <0.125 to 8 <0.125 to 8 <0.125 to 8 <0.125 to 8 <0.125 to 8
n resistant (%) 4 (22.2) 6 (33.3) 9 (50) 6 (33.3) 3 (16.7) 4 (22.2)
P 0.4049 0.0450 0.2051 0.0368 0.0001 0.0136
1MIC50, MIC90, and ranges expressed in g/mL.
milliliter of 10−3 to 10−7 dilutions of homogenates was
tested in poured plates of Fluorocult agar prepared as
specified by the manufacturer (Merck). After the agar had
solidified, the plates were overlaid with 3 to 4 mL of
melted Fluorocult and incubated at 44°C for 24 h. After
incubation, pink to red colonies showing blue florescence
after exposure to a 365-nm UV lamp were considered as
E. coli.
After incubation, 3 typical colonies were harvested and
transferred onto Columbia agar with 50 g/kg of sheep
blood (BioMérieux, Marcy l‘Etoile, France) and incubated
at 44°C for 24 h to obtain pure cultures. This was done
for each batch of chickens (3 chickens) on each sampling
day (18 strains per group and day). Thus, a total of 648
strains were obtained (216 strains per antimicrobial
tested).
These pure cultures were characterized by colony and
cell morphologies, Gram stain, methyl red, citrate test,
oxidase, and catalase activities, and indole production.
Positive strains were confirmed by API 20E (BioMérieux).
All isolates were stored at −80°C until further analysis




Antimicrobial susceptibility testing was performed us-
ing a broth microdilution susceptibility test in microtiter
plates to determine minimum inhibitory concentrations
(MIC). The MIC and levels of resistance were determined
according to the recommendations of the Clinical and
Laboratory Standards Institute (CLSI, formerly NCCLS,
2002). Standard antimicrobial dilutions were obtained
with an enrofloxacin reference standard (Bayer AG, Lev-
erkusen, Germany), doxycycline (Fluka, St Gallen, Swit-
zerland), and sulfisoxazole (Sigma Chemical Co, St. Louis,
MO). The final concentration ranges were 0.008 to 64
gmL−1 for enrofloxacin, 0.25 to 128 gmL−1 for doxycy-
cline, and 4 to 2,048 gmL−1 for sulfisoxazole. Each tray
also contained a positive and a negative growth control
well.
The microtiter plates were incubated for 18 to 24 h at
37°C with a source of moisture to prevent dehydration.
The MIC were determined by visual observation of the
lowest concentration that yielded no visible growth for
enrofloxacin and doxycycline in the wells. For sulfisoxa-
zole, the MIC was defined as the concentration of the
drug that elicited approximately 80% inhibition of growth
in the well as compared with the growth in the control
wells with no drug added. The breakpoints used were
those recommended by the CLSI (formerly NCCLS, 2002)
for veterinary pathogens: ≥2 gmL−1 for enrofloxacin,
≥16 gmL−1 for doxycycline, and ≥512 gmL−1 for sulfi-
soxazole. The MIC that inhibited 50% (MIC50) and 90%
(MIC90) of total strains were calculated from the MIC
values.
Target MIC ranges were verified with E. coli ATCC
25922 reference strain as quality control. Quality control
was considered acceptable if the results obtained were
within ranges recommended by the CLSI (NCCLS, 2002).
Statistical Analysis
The amounts of water ingested by the treated and con-
trol chickens were compared using an unpaired Student’s
t-test. The distributions of resistant strains were com-
pared by means of the χ2 test and Fisher’s exact test.
Differences were considered significant when probabili-
ties were lower than 0.05. All statistical analyses were
carried out using Statgraphics version 5.0.1. (SAS Insti-
tute, Cary, NC).
RESULTS AND DISCUSSION
The total consumption of the antimicrobials tested by
the treated chickens during all of the treatments was 31.07
mg in the case of enrofloxacin (SD = 13.136) 42.97 mg in
the case of doxycycline (SD = 13.28) and 870.02 mg in the
case of sulfonamides (SD = 254.42). Taking into account
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Table 2. Minimum inhibitory concentration (MIC) for 50% (MIC50) and 90% (MIC90), MIC ranges and resistance
rates for Escherichia coli strains obtained from treated and control chickens during and after doxycycline applica-
tion in the drinking water1
Sampling day
Item 0 1 3 5 8 12
Treated chickens
n strains 17 18 16 18 18 18
MIC50 2 4 8 4 8 8
MIC90 16 8 16 16 16 16
Range <0.25 to 16 <0.25 to 16 <0.125 to 16 0.5 to 16 <0.25 to 16 <0.25 to 32
n resistant (%) 3 (17.6) 2 (11.1) 6 (37.5) 4 (22.2) 6 (33.3) 8 (44.4)
Control chickens
n strains 15 17 18 18 18 18
MIC50 2 1 1 2 4 4
MIC90 4 8 8 4 8 16
Range <0.25–4 <0.25–16 <0.25–8 <0.25–8 0.5–32 <0.25–16
n resistant (%) 0 (0) 2 (11.8) 1 (5.6) 0 (0) 1 (5.6) 3 (16.7)
P 0.1773 0.4410 0.0214 0.0354 0.0272 0.1648
1MIC50, MIC90, and ranges expressed in g/mL.
the average weights of the chickens employed for the
treatments [552 g (SD = 114.32) for the case of enrofloxa-
cin, 638 g (SD = 109.26) for the case of doxycycline, and
678 g (SD = 175.26) for the case of sulphonamides], the
real dose ingested expressed as mg/kg of BW and day
was 11.25 in the case of enrofloxacin, 13.47 in the case of
doxycycline, and 183.32 in the case of sulphonamides.
The results obtained for the MIC50, MIC90, MIC ranges
and resistance rates are shown in Tables 1 to 3 for en-
rofloxacin, doxycycline, and sulphonamides, respec-
tively. There were no significant differences between the
control and treated batches in regards to the MIC profile
on d 0. Likewise, as expected there were no significant
differences in the control batches between different days
during the assay.
Immediately after starting the enrofloxacin treatment,
pre-existing resistant E. coli populations presents in the
chicken guts were rapidly selected and this resistance
was maintained until the end of the withdrawal period
(88.9 vs. 22.2% in the control batches). Thus, significant
differences were obtained from d 1 to 17 with respect to
the resistance rates of the treated and control chickens.
Table 3. Minimum inhibitory concentration (MIC) for 50% (MIC50) and 90% (MIC90), MIC ranges and resistance rates for Escherichia coli strains
obtained from treated and control chickens during and after sulphonamides application in the drinking water1
Sampling day
Item 0 1 4 9 16 24
Treated chickens
n strains 18 18 18 18 18 18
MIC50 512 512 1,024 1,024 1,024 1,024
MIC90 2,048 1,024 2,048 1,024 2,048 2,048
Range <4 to 2,048 <4 to 2,048 512 to 2,048 512 to > 2,048 <4 to 2,048 <4 to > 2,048
n resistant (%) 11 (61.1) 13 (72.2) 18 (100) 18 (100) 16 (88.8) 17 (94.4)
Control chickens
n strains 18 18 18 17 18 18
MIC50 512 <4 <4 <4 <4 512
MIC90 1,024 <4 1,024 1,024 1,024 1,024
Range <4 to 2,048 <4 to 1,024 <4 to 1,024 <4 to 2,048 <4 to 2,048 <4 to 2,048
n resistant (%) 10 (55.6) 2 (11.1) 9 (50) 7 (41.2) 9 (50) 11 (61.1)
P 0.0663 0.0009 0.0018 0.0019 0.0153 0.0959
1MIC50, MIC90, and ranges expressed in g/mL.
The resistance rates reached their highest value for treated
poultry on d 5 (88.9%), thereafter remaining at this level
until d 17.
The E. coli resistance rates to enrofloxacin obtained in
this work before starting treatment were higher than
those reported by the European surveillance pro-
grammes. However, these rates are in agreement with
previous data reported by other authors (Barrow et al.,
1998; Moniri and Dastehgoli, 2005). In recent years, an
increase in the resistance of E. coli to quinolones has been
reported [i.e., the 10% ciprofloxacin resistance described
in the Netherlands (Van den Bogaard et al., 2001) or the
38% ciprofloxacin resistance in E. coli isolated from Span-
ish supermarket poultry retail products in Spain (Sáenz
et al., 2001)].
This increase in the resistance of E. coli to quinolones
seems to be caused by the widespread use of these antimi-
crobials for veterinary purposes. It has been documented
that ciprofloxacin resistance is higher in E. coli isolated
from broilers than the microorganisms isolated from
other sources, such as pigs and humans. This could be
due to the higher use of quinolones in chickens than in
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pigs or humans (Sáenz et al., 2001; Kijima-Tanaka et al.,
2003). Also, a recent work has shown that quinolone resis-
tance in E. coli isolated from broilers previously dosed
with quinolones was significantly higher than the resis-
tance of E. coli isolated from poultry without exposure
to quinolones (49.5 vs. 33.7%, respectively; Moniri and
Dastehgoli, 2005).
In the case of doxycycline treatment, although the in-
crease in resistance rates in E. coli isolated from treated
chickens was less evident than in the case of enrofloxacin,
significant differences in the resistance rates of the treated
and control chickens were observed on d 3, 5, and 8. These
resistance rates reached their highest value for treated
poultry at the end of the withdrawal period (44.4%).
In recent years, bacterial resistance to doxycycline has
been widely documented in the case of certain respiratory
pathogens (Chopra and Roberts, 2001; Cunha, 2003; Jones
et al., 2004; Koeth et al., 2004). However, only a few au-
thors have addressed such resistance in enteric pathogens
of animal origin, such as E. coli. In this sense, it is crucial
to gain a deeper knowledge about resistance of zoonotic
bacteria to this antimicrobial agent because doxycycline
is widely used in veterinary medicine, especially in the
case of chickens and turkeys and specially in developing
nations (Chopra and Roberts, 2001). The resistance rates
determined in this work before the start of treatment were
relatively low as compared with those found by other
authors for tetracyclines in E. coli isolated from poultry
feces [i.e., 75 or 43.8% of resistance of E. coli to tetracycline
obtained by other authors for broilers in Spain (Sáenz et
al., 2001; Bywater et al., 2004)]. Nevertheless, the resis-
tance rates determined in our work may not contradict
such reports because some tetracycline-resistant bacteria
may be sensitive to doxycycline (NCCLS, 2002).
As in the cases described above, immediately after
starting the sulphonamides treatment, pre-existing sulf-
phonamide-resistant E. coli populations were rapidly se-
lected, and this resistance was maintained until the end
of the withdrawal period (94.4 vs. 61.1% in the control
batches). In addition, significant differences between the
resistance rates of the treated and control chickens were
observed from d 1 to 16. Resistance rates reached the
highest values for the treated poultry on d 4 and 9 (100%).
The resistance rates obtained in this study before starting
treatment and in the control batches (55.6 and 61.1%,
respectively) were in agreement with previously reported
data, such as the 69.7% of sulfadimethoxine-resistant
strains observed in E. coli isolated from poultry in Japan.
Likewise, 52.1% resistance to trimethoprim-sulfamethox-
azole was determined in E. coli isolated from broilers in
Spain (Kijima-Tanaka et al., 2003; Bywater et al., 2004).
According to these results, during the 3 treatments eval-
uated, pre-existing resistant E. coli populations were rap-
idly selected and these resistances were maintained until
the end of the withdrawal period. Taking into account
that at the time of slaughter poultry meat may be easily
contaminated with fecal E. coli (Sáenz et al., 2001; Van
den Bogaard et al., 2001) and the fact that treated chickens
are often sent to the slaughterhouse immediately after
the withdrawal period, the resistant bacteria selected by
the antimicrobial treatments could be a risk for public
health after poultry slaughter and processing.
Moreover, the resistant E. coli strains selected by the
antimicrobial treatments might reach humans via other
animals, sewage, or other humans, such as farmers or
slaughterers (Phillips et al., 2003). According to the results
obtained in the present work, such indirect ways of trans-
mission could be considered as potential ways of trans-
mission of resistant bacteria to human beings.
Taking into account that after the EC banned the use
of antimicrobials as growth promoters, an increment of
quantities consumed of antimicrobials used as therapeu-
tics was expected and an undesirable consequence of this
prohibition would be the loss of efficacy of these antimi-
crobial agents. Thus, although more microbiological stud-
ies are necessary, it seems advisable to extend the with-
drawal period after the implementation of antimicrobial
poultry therapy, as well as an adequate control of sew-
age use.
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